CN101052405A - 用于高脂血症的聚壳糖胺与hmg－coa还原酶抑制剂的组合 - Google Patents

用于高脂血症的聚壳糖胺与hmg－coa还原酶抑制剂的组合 Download PDF

Info

Publication number
CN101052405A
CN101052405A CNA2005800365828A CN200580036582A CN101052405A CN 101052405 A CN101052405 A CN 101052405A CN A2005800365828 A CNA2005800365828 A CN A2005800365828A CN 200580036582 A CN200580036582 A CN 200580036582A CN 101052405 A CN101052405 A CN 101052405A
Authority
CN
China
Prior art keywords
coa reductase
reductase inhibitor
hmg
polychitosamine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800365828A
Other languages
English (en)
Chinese (zh)
Inventor
A·奥比
J-G·莱霍克斯
R·布瑞兹津斯奇
G·杜普尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DNP Canada Inc
Original Assignee
DNP Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DNP Canada Inc filed Critical DNP Canada Inc
Publication of CN101052405A publication Critical patent/CN101052405A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stereo-Broadcasting Methods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800365828A 2004-09-15 2005-09-14 用于高脂血症的聚壳糖胺与hmg－coa还原酶抑制剂的组合 Pending CN101052405A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60983004P 2004-09-15 2004-09-15
US60/609,830 2004-09-15

Publications (1)

Publication Number Publication Date
CN101052405A true CN101052405A (zh) 2007-10-10

Family

ID=36059676

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800365828A Pending CN101052405A (zh) 2004-09-15 2005-09-14 用于高脂血症的聚壳糖胺与hmg－coa还原酶抑制剂的组合

Country Status (8)

Country Link
US (5) US20060058261A1 (enExample)
EP (1) EP1812019A4 (enExample)
JP (1) JP2008513379A (enExample)
CN (1) CN101052405A (enExample)
AU (1) AU2005284565A1 (enExample)
BR (1) BRPI0515443A (enExample)
CA (1) CA2580460A1 (enExample)
WO (1) WO2006029524A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
CN105859639A (zh) 2009-03-18 2016-08-17 雷斯韦洛吉克斯公司 新的抗炎剂
US9078849B2 (en) 2009-04-08 2015-07-14 Nanyang Polytechnic Plant extract comprising statins and preparation techniques and uses thereof
EP2718331B1 (en) 2011-06-13 2017-08-02 Rival S.E.C N,n,n-trialkylpolymers, methods of their preparation and uses thereof
EP3856626B1 (en) * 2018-09-26 2024-05-15 TQ-Systems GmbH Method and device for dynamically controlling a range of an electrically-assisted bicycle, electrically-assisted bicycle
IT201900021291A1 (it) * 2019-11-15 2021-05-15 Biomedica Pharma Gmbh Chitosano e prodotto medicale per l’uso in un metodo di prevenzione o trattamento di una malattia cardiovascolare

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903140A (en) * 1970-09-08 1975-09-02 Alza Corp Diazadodecane prostaglandin compounds
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
NZ257762A (en) * 1992-12-01 1997-03-24 Minnesota Mining & Mfg Antimicrobial metal complex comprising a chelating polymer one or more transition metals and a potentiator; use in a water-absorbing porous article (e.g. a sponge)
FI107432B (fi) * 1997-02-06 2001-08-15 Novasso Oy Mikrokiteisen kitosaanin käyttö
FI982291L (fi) * 1998-10-23 2000-04-24 Novasso Oy Aine kolesterolin sekä lipidien pitoisuuden alentamiseksi
US20020016307A1 (en) * 1999-10-27 2002-02-07 Mullins John Jason Gentry Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity
US6777552B2 (en) * 2001-08-16 2004-08-17 Teva Pharmaceutical Industries, Ltd. Processes for preparing calcium salt forms of statins
US6933291B2 (en) * 2000-12-01 2005-08-23 N.V. Nutricia Cholesterol lowering supplement
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition

Also Published As

Publication number Publication date
AU2005284565A1 (en) 2006-03-23
BRPI0515443A (pt) 2008-07-29
WO2006029524A1 (en) 2006-03-23
US20130244973A1 (en) 2013-09-19
US20090197830A1 (en) 2009-08-06
EP1812019A4 (en) 2007-12-26
US20120258932A1 (en) 2012-10-11
US20060058261A1 (en) 2006-03-16
US20110028429A1 (en) 2011-02-03
EP1812019A1 (en) 2007-08-01
JP2008513379A (ja) 2008-05-01
CA2580460A1 (en) 2006-03-23

Similar Documents

Publication Publication Date Title
CN1124134C (zh) 柚苷和柚苷配基作为肝病的预防或治疗剂的应用
DE60126829T2 (de) Kombination von drei Substanzen zur Vorbeugung und Behandlung von Arthritis
US20120258932A1 (en) Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
JPWO2006059730A1 (ja) 体脂肪減少用組成物
CN1278170A (zh) 作为酰基CoA－胆固醇－O－酰基转移酶抑制剂、巨噬细胞－脂质复合物在动脉壁上累积的抑制剂以及肝病的预防或治疗剂的橙皮苷或橙皮素
JP2003155244A (ja) モズク由来のフコイダンを含む食品
US20090054373A1 (en) Chitin derivatives for hyperlipidemia
JP2006506464A (ja) 食事性繊維およびコレステロール低下物質で造られたコレステロール低下剤
HK1114007A (en) Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia
US20080293671A1 (en) Combination of Polychitosamine and Fibrate for the Prevention and Treatment of Hyperlipidemia
JP2004067575A (ja) 糖尿病治療薬効果促進剤
CN1953670B (zh) 组合物、组合物的用途以及治疗肥胖症的方法
HK1126389A (en) Combination of polychitosamine and fibrate for the prevention and treatment of hyperlipidemia
JP2011241216A (ja) モズク由来のフコイダンを含む食品
JP4575105B2 (ja) 骨芽細胞活性抑制剤
EP0803202A2 (en) Dietary composition containing chitosan, Garcinia cambogia hydroxycitrate and organic chromium
JP2011046647A (ja) ポリ−γ−グルタミン酸を含有するコレステロール抑制剤
JP2002212094A (ja) コレステロール生成抑制剤及びその製造方法
JP2006306792A (ja) 肝機能保護剤又は改善剤
HK1073261A (en) Nutrient therapy for immuno-compromised patients
HK1022104B (en) Hesperidin and hesperetin as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
HK1022104A1 (zh) 作为3-羟基-3-甲基戊二酰基coa(hmg-coa)还原酶抑制剂的橙皮苷和橙皮素

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1114007

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20071010